IDEXX Laboratories, Inc. $IDXX Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 59,590 shares of the company’s stock after selling 15,176 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in IDEXX Laboratories were worth $38,071,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. UniSuper Management Pty Ltd lifted its stake in shares of IDEXX Laboratories by 23.4% during the 3rd quarter. UniSuper Management Pty Ltd now owns 8,564 shares of the company’s stock worth $5,471,000 after purchasing an additional 1,624 shares during the period. Drive Wealth Management LLC acquired a new position in IDEXX Laboratories in the third quarter valued at $202,000. Westfuller Advisors LLC purchased a new position in IDEXX Laboratories during the third quarter worth about $155,000. Teacher Retirement System of Texas lifted its position in IDEXX Laboratories by 7.1% during the third quarter. Teacher Retirement System of Texas now owns 35,466 shares of the company’s stock worth $22,659,000 after buying an additional 2,344 shares during the period. Finally, Hudson Value Partners LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter worth about $224,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Leerink Partners set a $785.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. JPMorgan Chase & Co. boosted their price objective on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, January 12th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $763.50.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. This represents a 30.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Up 0.4%

Shares of IDEXX Laboratories stock opened at $693.85 on Monday. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The stock has a market cap of $55.40 billion, a price-to-earnings ratio of 55.02, a price-to-earnings-growth ratio of 3.71 and a beta of 1.67. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24. The company has a fifty day moving average price of $705.83 and a 200 day moving average price of $656.34.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the company posted $2.80 earnings per share. The firm’s revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.